Based on its own intellectual property rights, the digital PCR system developed by the company has won the first NMPA Class III medical device registration certificate for SARS-Cov-2 detection reagents based on digital PCR technology, and won the Gold Award of China In Vitro Diagnostic Excellent Innovation Product for two consecutive years and the overall champion of Zhongguancun International Frontier Science and Technology Innovation Competition. We are committed to be a leading life science and molecular diagnostic company, serving life science, precision medicine, drug development and health management by developing multi-indicator, high-throughput, automated, anti-contamination and lowcost molecular diagnostic technologies.